Nivolumab

For patients with metastatic melanoma who fail to durably respond to PD-1 inhibitors, fecal microbiota transplantation (FMT) combined with reintroduction of anti-PD-1 therapy seems promising.

Neoadjuvant nivolumab was safe, and yielded pathologic responses in patients with resectable lung cancer.

The neoadjuvant PD-1 blockade in resectable lung cancer led to major pathological responses in 45 percent of the patients enrolled in a clinical trial.

KEYNOTE-189 met its dual primary endpoints of overall survival and progression-free survival in newly diagnosed metastatic NSCLC.

Patients with newly diagnosed advanced NSCLC with high tumor mutational burden had significantly improved PFS with nivolumab plus ipilimumab.

Combinations of immune checkpoint inhibitors and chemotherapy show promising results. Results of the the KEYNOE 189 study will be presented at the AACR.

Immune checkpoint inhibitors show promise in the treatment of rare mCRC cases with high microsatellite instability.